Volume 24, Number 4—April 2018
Dispatch
Imipenem Resistance in Clostridium difficile Ribotype 017, Portugal
Table 1
Hospital |
Resistance breakpoint† |
Antimicrobial drug, MIC breakpoints, mg/L |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
IMP‡ | ETP‡ | MRP‡ | MXF†§ | MTZ†§ | VAN†§ | CLI‡ | CHL‡ | RIF† | TGC† | TET‡ | ||
>16 |
>16 |
>16 |
>4 |
>2 |
>2 |
>8 |
>32 |
>0.004 |
>0.25 |
>16 |
||
A, 22 isolates |
MIC range | >32 | 3–16 | 1.5–4 | >32 | <0.016–1 | 0.38–2 | >256 | 2–6 | >32 | <0.016–0.094 | 16–32 |
GM MIC | 32 | 7.56 | 2.31 | 32 | 0.12 | 0.73 | 256 | 3.29 | 32 | 0.025 | 18.08 | |
MIC90 | 32 | 12 | 3 | >32 | 0.38 | 2 | 256 | 4 | 32 | 0.032 | 32 | |
MIC50 | 32 | 6 | 2 | >32 | 0.19 | 0.75 | 256 | 3 | 32 | 0.023 | 16 | |
% Resistant |
100 |
4.5 |
0 |
100 |
0 |
0 |
100 |
0 |
100 |
0 |
100 |
|
B, 3 isolates |
MIC range | 1.5–3 | 1.5–2 | 0.5–1.5 | 1.5 | <0.016–0.25 | 0.38–0.75 | >256 | 3–4 | >32 | <0.016–0.023 | 16 |
GM MIC | 2.08 | 1.82 | 0.83 | 1.5 | 0.072 | 0.60 | 256 | 3.30 | 32 | 0.020 | 16 | |
MIC90 | 3 | 2 | 1.5 | 1.5 | 0.25 | 0.75 | 256 | 4 | 32 | 0.023 | 16 | |
MIC50 | 2 | 2 | 0.75 | 1.5 | 0.094 | 0.75 | 256 | 3 | 32 | 0.023 | 16 | |
% Resistant |
0 |
0 |
0 |
0 |
0 |
0 |
100 |
0 |
100 |
0 |
100 |
|
p value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | 0.45 | 0.56 | ND | 0.98 | ND | 0.41 | 0.51 |
*CHL, chloramphenicol; CLI, clindamycin; ETP, ertapenem; GM, geometric mean; IMP, imipenem; MIC50, minimal inhibitory concentration for 50% of strains; MIC90, minimal inhibitory concentration for 90% of strains; MRP, meropenem; MTZ, metronidazole; MXF, moxifloxacin; ND, not done; RIF, rifampin; TGC, tigecycline; VAN, vancomycin.
†European Committee on Antimicrobial Susceptibility Testing breakpoint.
‡Clinical and Laboratory Standards Institute breakpoint.
§Previously determined (9).
References
- European Centre for Disease Prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals, 2011–2012. Stockholm: The Centre; 2013.
- Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020. DOIPubMedGoogle Scholar
- Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2014;69:881–91. DOIPubMedGoogle Scholar
- Spigaglia P. Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection. Ther Adv Infect Dis. 2016;3:23–42. DOIPubMedGoogle Scholar
- Gerding DN, Lessa FC. The epidemiology of Clostridium difficile infection inside and outside health care institutions. Infect Dis Clin North Am. 2015;29:37–50. DOIPubMedGoogle Scholar
- Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev. 2010;23:529–49. DOIPubMedGoogle Scholar
- King AM, Mackin KE, Lyras D. Emergence of toxin A-negative, toxin B-positive Clostridium difficile strains: epidemiological and clinical considerations. Future Microbiol. 2015;10:1–4. DOIPubMedGoogle Scholar
- Freeman J, Vernon J, Morris K, Nicholson S, Todhunter S, Longshaw C, et al.; Pan-European Longitudinal Surveillance of Antibiotic Resistance among Prevalent Clostridium difficile Ribotypes’ Study Group. Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clin Microbiol Infect. 2015;21:248.e9–16. DOIPubMedGoogle Scholar
- Santos A, Isidro J, Silva C, Boaventura L, Diogo J, Faustino A, et al. Molecular and epidemiologic study of Clostridium difficile reveals unusual heterogeneity in clinical strains circulating in different regions in Portugal. Clin Microbiol Infect. 2016;22:695–700. DOIPubMedGoogle Scholar
- Lee JH, Lee Y, Lee K, Riley TV, Kim H. The changes of PCR ribotype and antimicrobial resistance of Clostridium difficile in a tertiary care hospital over 10 years. J Med Microbiol. 2014;63:819–23. DOIPubMedGoogle Scholar
- He M, Sebaihia M, Lawley TD, Stabler RA, Dawson LF, Martin MJ, et al. Evolutionary dynamics of Clostridium difficile over short and long time scales. Proc Natl Acad Sci U S A. 2010;107:7527–32. DOIPubMedGoogle Scholar
- Zapun A, Contreras-Martel C, Vernet T. Penicillin-binding proteins and β-lactam resistance. FEMS Microbiol Rev. 2008;32:361–85. DOIPubMedGoogle Scholar
- Serrano M, Kint N, Pereira FC, Saujet L, Boudry P, Dupuy B, et al. A recombination directionality factor controls the cell type-specific activation of σK and the fidelity of spore development in Clostridium difficile. PLoS Genet. 2016;12:e1006312. DOIPubMedGoogle Scholar
- He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet. 2013;45:109–13. DOIPubMedGoogle Scholar
Page created: March 16, 2018
Page updated: March 16, 2018
Page reviewed: March 16, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.